A kidney cancer prediction model to guide treatment decisions, including for patients with tumor thrombus
Official title: Emulated-target Trial for Guiding Stratified Treatment for Renal Cell Carcinoma With Venous Tumor Thrombus
Run by Peking University Third Hospital · NCT07117227 · Data updated 2026-11-12
This project will test whether a new prediction model can guide treatment choices to improve survival for adults with renal cell carcinoma, including those with venous tumor thrombus.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 4700 (estimated) |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | February 1, 2027 |
| Study ends | August 1, 2027 |
| Registry record updated | April 14, 2026 |
| Trial ID | NCT07117227 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–80 with primary renal cell carcinoma who underwent radical or nephron-sparing nephrectomy and have complete clinical data are ideal candidates.
✕Probably not a fit
Patients with distant metastasis at baseline, a history of other malignancies, severely missing clinical records, or who discontinue adjuvant treatment early are excluded and unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center observational analysis using real-world data from about 4,700 RCC patients treated at Peking University Third Hospital from 2012–2026. Researchers will develop and validate a prognostic model for RCC (including a venous tumor thrombus subgroup), compare its discrimination and calibration against existing published models, and examine model stability. An emulated target trial framework will be used to compare outcomes of risk-stratified adjuvant treatment (high/medium/low risk) versus non-stratified treatment, with survival and health-economic endpoints. The cohort includes adults 18–80 years who underwent radical or partial nephrectomy and excludes patients with distant metastasis at baseline or severely incomplete records.
Why it matters
Potential benefit: If successful, the model could help doctors personalize adjuvant treatment so higher-risk patients get more aggressive therapy while lower-risk patients avoid unnecessary treatment.
How similar studies have gone: Several published RCC prognostic models exist and have shown variable predictive performance, but applying an emulated target trial to test model-guided treatment in RCC is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults ≥18 years of age; * Diagnosis of primary renal cell carcinoma before and during the surgery; * Received radical nephrectomy/nephron-sparing surgery. Exclusion Criteria: * Subjects with severely missing clinical information; * History of other malignant tumors. * Recurrence observed before first postoperative follow-up. * Discontinue the adjuvant treatment within in the first two course because of severe adverse react.
Where it's running
-
Peking University Third Hospital
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Principal investigator: Shudong Zhang, master — Peking University Third Hospital
- Study coordinator: Jiyuan Chen, master
- Email: chenjiyuan@pku.edu.cn
- Phone: +086 18801430995
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance
This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.
-
Iruplinalkib for ALK-positive advanced lung adenocarcinoma after lorlatinib
We will try iruplinalkib in adults with advanced ALK-positive lung adenocarcinoma who progressed on or couldn't tolerate lorlatinib to see how well it works and how safe it is in routine care.
-
177Lu-TLX250 for advanced relapsed or recurrent clear-cell kidney cancer
This will test whether 177Lu-TLX250, a CAIX-targeting radioligand, helps adults with CAIX-positive advanced or relapsed clear-cell kidney cancer who have had 2–3 prior therapies.
-
Cadonilimab and Lenvatinib in advanced kidney cancer
This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.
-
Nectin-4 PET/CT imaging to differentiate renal tumors
This study tests a new PET tracer, 18F-N230A, to see if it helps distinguish renal cell carcinoma from renal pelvic urothelial carcinoma in adults.
-
Geniculate Artery Embolization for Knee Osteoarthritis in Cancer Patients
This study tests whether blocking knee blood vessels with a standard care procedure can help reduce pain and improve function in people with knee osteoarthritis who also have cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.